2nd World Congress on Diabetes and Pediatric Endocrinology
The opportunity to network with eminent researchers, academics, scientific societies, therapists, counsellors, delegates, teachers, business professionals, and other executives who are authorities on endocrinology and diabetes is tremendous at Pediatric Endocrinology 2023.
Welcome to Conference Series that continues its commitment to providing sincere and trustworthy contributions to the scientific community through its Open Access Initiative.
Conference Series publishes 700+ open access journals with over 100,000 notable figures and renowned scientists on the editorial board and organises 1000+ conferences annually across the USA, Europe, and Asia with the help of 1000 more scientific societies.
The September 25-26, 2023, Paris, France, “World Congress on Diabetes and Pediatric Endocrinology” will feature symposiums, keynote addresses, plenary talks, poster sessions, and panel discussions on the most recent advancements in the study of diabetes and endocrine disorders.
Students, faculty, deans, researchers, and leaders in the fields of diabetes and pediatric endocrinology can work together at this conference on issues relating to these conditions. The range of oral and poster presentations will provide attendees with opportunity to learn about endocrinology and diabetes research. Meet and socialize with nurses of all levels, from new graduates to deans, professors, and researchers. This is your finest chance to connect with the biggest group of attendees from the Pediatric Endocrinology 2023.
CEOs, Directors of Associations and Societies, Scientists, Doctors, Professors, Nurses, Diabetes Practitioners, Surgeons, Young Researchers, Industrial Delegates, Pharmaceutical Industries, Herbal Institutes, Herbal Research Centers, Healthcare Industries, Pharmacological and Pharmacognosy Industries, Nurses, Diabetes Practitioners, Medical Students, Surgeons, Young Researchers, Industrial Delegates.
The Conference’s goal is:
To exchange their insights and research discoveries on all sides of metabolic syndromes and diabetes, it makes an effort to bring together top academics, researchers, medical professionals, and research scientists. Additionally, it offers a top multidisciplinary arena for academics, experts, medical professionals, and educators to discuss and share the most recent diabetes treatment methods.
Abstract Qualification Standards
Eligibility for authors:
As the primary author, one person may submit up to two standard abstracts.
An infinite number of abstracts for trials in progress may be submitted by individuals.
A person may be a co-author on as many abstracts as they choose.
Research on metabolic syndrome, endocrinology, medicine, and health are all welcome.
Abstracts should include primary scientific data, describe clinical observations, or address scientific questions.
Only if significant new information can be demonstrated, data from the long-term follow-up of previously published clinical trials may be submitted.
A prospective randomised clinical trial’s interim analysis will be taken into account if it is carried out according to the original protocol and is statistically sound.
It is best to integrate the abstracts of themes that are clinically related.
Note: If you submit more than one abstract for the same subject, you risk having one or more of them rejected.
Conditions for Submission:
Your full name, academic degree(s), institution, address, email address, and most current photo should all be provided. All upcoming communication from us on the position of your abstract will be sent to you.
The conference proceedings will include the selected abstracts.
Session & Track
Track 1: Advanced Diabetes Treatment Technologies
Track 2: Case Reports and Others
Track 3: Chronic Complication of Diabetes
Track 4: Children, Teens, and Adolescents with Thyroid Disorders
Track 5: Clinical Diabetes Practice and Research
Track 6: COVID-19 and diabetes
Track 7: Diabetes
Track 8: Diabetes Types
Track 9: Diabetes Disease Disorder in Endocrinology
Track 10: Diabetes Stem Cell Therapy
Track 11: Diabetes with the Ketogenic Diet
Track 12: Diabetes Genetics
Track 13: Endocrine Diseases Treatment & Diagnosis
Track 14: Emerging Diabetic Research Focus
Track 15: Gestational Diabetes
Track 16: Insulin Treatment
Track 17: Nursing Diabetes
Track 18: Ophthalmology and Diabetes
Track 19: Pediatric Endocrinology
Track 20: The Health Effects of Obesity
Market size and analysis for endocrine disorders
During the forecast period, the market for endocrine diseases is anticipated to increase significantly. Global geriatric, diabetes, and obesity rates are predicted to increase, which would help the market expand. Technology advancements, such as the creation of simple-to-use test kits, helped the uptake of user- and money-friendly home-based diagnostics. According to the International Federation, there will be 783 million adults with diabetes worldwide by 2045, up from the estimated 537 million in 2022. The acceptance of testing for the insulin hormone will rise as diabetes rates rise globally, which is expected to accelerate market expansion.
During the projected period of 2022–2029, Data Bridge Market Research examines the growth rate of the global market for endocrine diseases. During the aforementioned forecast period, the global market for endocrine disorders is anticipated to grow at a CAGR of almost 7.4%. The market had a 2022 valuation of USD 10.28 billion and was expected to reach USD 18.2 billion by 2029. Along with information about market conditions like market value and growth rate, The market studies compiled by Data Bridge Market Research not only include segmentation, regional coverage, and main players, but also in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Dynamics of the Global Endocrine Disorders Market:
Increasing Number of Parathyroid Conditions
200 million individuals worldwide suffer from thyroid disorders, primarily hyperthyroidism; in the majority of these nations, 50% of the population goes misdiagnosed. The elderly and women are more likely to have this illness. The global market for treating parathyroid illnesses is expected to rise as parathyroid diseases become more common. According to a recent study, Spain is expected to have had 12,903 individuals registered with parathyroid gland disorders and 13,897 admissions between 2003 and 2017. Primary hyperparathyroidism (pHPT), according to studies from Informa U.K. Limited, is the third most common endocrine condition. This accelerates market expansion.
Increasing Oral Drug Demand
Oral medications are predicted to accelerate market expansion. Given that the majority of medications are accessible in capsule and tablet form and that this is a very practical mode of administration, the category is anticipated to accelerate the global market.
Increasing Number of Seniors
The older population is expected to grow, which would increase market size. Younger folks between the ages of 30 and 40 and elderly people are more likely to have parathyroid disorders. Therefore, a rise in the older population will probably present chances for the expansion of the global industry. According to an article in the Endocrine Society journal, a retrospective study from January 1997 to June 2018 estimated that 462 patients had been diagnosed with primary hyperparathyroidism, and 212 of them were above the age of 65.
Research Activities Have Increased
The market for treatments for parathyroid disorders is expected to be driven by key industry players’ emphasis on R&D. For instance, in June 2017, Amgen, Inc. received a favorable recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the marketing authorization of Mimpara (cinacalcet), a pediatric formulation for secondary hyperparathyroidism in children aged three and older (HPT). As a result, these policies stimulate market expansion.
FDA Product Recall
The Food and Drug Administration’s (FDA) product recall has probably slowed the market’s expansion for parathyroid disease treatments worldwide. For instance, the Takeda Pharmaceutical Company Limited announced the NATPARA U.S. recall in September 2019. The potential problem with rubber particles emerging from the rubber septum of the NATPARA cartridge is what prompted the recall.
Limiting Hormone Therapy Adoption
Oral medicines are typically regarded as the best treatment for hypoparathyroidism. This limits the use of hormone therapy that is currently accessible. Additionally, long-term positive medication usage symptoms have yet to be identified in clinical trials, which may restrict patient uptake of therapy. Therapy with rhPTH (1-84) is a long-term management option, although further long-term efficacy and safety evidence are required in people, according to the Drug Literature Review 2018. As a result, it limits market expansion.
This report on the global endocrine disorders market details recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, and the effects of domestic and local market participants. It also analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, and product launches. Contact Data Bridge Market Research for an Analyst Brief to learn more about the global market for endocrine disorders. Our staff will assist you in making an informed choice to drive market expansion.
Market Size for Endocrine Disorders Worldwide
The global market for endocrine disorders is divided into segments based on end-user, distribution channel, drug class, method of administration, and treatment. The expansion of these divisions will enable you to study the industries’ scarce growth segments and give users a comprehensive market overview and industry insights to aid in the identification of key market applications.
Cushing’s Syndrome with Goiter
ovarian polycystic syndrome (PCOS)
Progesterone Replacement Therapy
Route of Administration
Past conference Report
Pediatric Endocrinology 2022 Report
Conference Series hosting the event “2nd World Congress on Diabetes and Pediatric Endocrinology” at Paris, France during September 25-26, 2023. The conferences were organized with a focus on the themes“Scrutinizing Recent Trends in Diabetes and Endocrinology” was a great success where eminent keynote speakers from various reputed companies and Universities made their resplendent presence and addressed the gathering.
The event proceedings were carried out through several Scientific-sessions and plenary lectures, Conference Series would like to express a sincere thankfulness to all the Honourable guests and Keynote Speakers of 2nd World Congress on Diabetes and Pediatric Endocrinology. We would like to convey a warm gratitude to all the Honourable guests and Keynote Speakers of Pediatric Endocrinology 2023.
Pediatric Endocrinology 2023 committee would like to convey a warm gratitude to all the Honourable guests and Keynote Speakers, Jason D. Gardner Louisiana State University Health Sciences Centre USA, Alexandra Lucas University of Florida USA, Helmy M. Siragy,, University of Virginia Health System USA, Masayoshi Yamaguchi,, Emory University USA, Heinrich Taegtmeyer,, University of Texas USA, have given a wonderful talk which makes allows the delegates and other attendees to gain the knowledge about main course of the event.
Pediatric Endocrinology 2023 Organizing Committee would like to thank the Moderator of the conference Scrutinizing Recent Trends in Diabetes and Endocrinology, who contributed a lot for the smooth functioning of this event and for taking up the responsibility to coordinate during the sessions for smooth functioning of this event. We are indebted to your support.
Conference Series also took the privilege of Pediatric Endocrinology 2023 Organizing Committee, Keynote Speakers, Plenary Speakers, Chairs and Co-Chairs, Young Researchers and other attendees whose support made the conference a great success.
We also would like to thank all our Speakers, Poster Presenters and Delegates for taking out your time and sharing their research work with our peer network. We are very glad to have shared a great relationship with all these Attendees, associations and we hope to see even greater support in our upcoming events. We would also like to thank Chairs and Co-chairs of the conference, Luisa Mestroni,, University of Colorado USA, Mehran Roxana,, Mount Sinai University USA, Sarah X. Zhang,, State University of New York USA for a being a great support for our event to be a grand success.
A series of lectures by distinguished professionals discussed the recent trends and issues in inter-disciplinary Paediatric Endocrinology and its technical advancements.
Save your dates for the most awaited event of 2023
With a great response and feedback which we received from participants and supporters from Pediatric Endocrinology 2022, we are proud to announce our upcoming conferences in the Series 2nd World Congress on Diabetes and Pediatric Endocrinology in Paris, France with the theme of Scrutinizing Recent Trends in Diabetes and Endocrinology
Some of our conference images are as follows:
The main aim of this conference is to solicit the gracious presence of our honourable, to the upcoming conference “2nd World Congress on Diabetes and Pediatric Endocrinology” that is going to be held during September 25-26, 2023 in Paris, France, to share and exchange their knowledge.
It is an International platform for business delegates, B2B meetings, poster presentations, workshops, symposia, networking and more. It will offer a platform wherein you can ensure enormous exposure and networking by exhibiting products and services. Grab the opportunities, and share your innovative ideas, new technologies and recent researches.
Pediatric Endocrinology 2023 witnesses an amalgamation of peerless speakers who enlightened the gathering with their contribution towards the prevention of Paediatric related difficulties, its effects and treatment on Diabetes.
For being a Experts Paediatric in and Diabetes, we hope that this platform gives knowledge and new updates by undergoing with the several interactive sessions to encourage the exchange of innovative ideas in the field of Rheumatology and its advancements, in that all the session talks are consider to be a great talks which makes the delegates, exhibitor, collaborators and other speakers feels so much interesting.
Being a significant expert in this area we would like to Invite you as an International Organizing Committee Members, Speakers, Keynote speakers, Young Research forum, Sponsors and Exhibitor, etc. for Paediatric Endocrinology 2023 . Our goal is to deliver an outstanding program which covers the entire spectrum of research & innovations in Otology, Rhinology, and Laryngology and share the cross-cultural experiences of various principles and practices.
The centre of the activity of Pediatric Endocrinology 2023 is to produce the clear visual definition by undergoing with Oral Presentation, Poster presentation, Workshop, Exhibition, networking and interacting session
With the feedback from your renowned Speakers, we have added some of the new Session tracks that needs to be focused such as such as Advanced Diabetes Treatment Technologies, Case Reports and Others, Chronic Complication of Diabetes, Children, Teens, and Adolescents with Thyroid Disorders, Clinical Diabetes Practice and Research,
With the great support we have successfully completed Pediatric Endocrinology 2023 and we are expecting huge response and support from the Diabetes and Paediatric Doctors, and Diabetes Paediatric Professionals, Young researchers, Students, Delegates, Directors and other Diabetes and Paediatric related companies to have your gracious presence at on Paediatric Endocrinology September 25-26, 2023 in Paris, France to make this congress a great successful event of the year 2023
Join our team Pediatric Endocrinology 2023 at this beautiful city of Paris, France and let’s make this professional gathering a Great success
Pediatric Endocrinology 2023